ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1498

Wisp-1 Neutralization Reduces Gvhd-Induced Skin Fibrosis by Altering TSLP-OX40L Axis-Dependent Th2 Responses

Raphael Lemaire, Tim Burwell, Rachel Griffin, Julie Bakken, Joseph Madary, Lynne Murray, Ronald Herbst and Jane Connor, Research, MedImmune LLC, Gaithersburg, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: fibroblasts and scleroderma, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is accumulating evidence for a role of Wnt-signaling pathway activation in connective tissue disorders, including dermal and lung fibrosis. In particular, expression of WNT1-inducible signaling protein–1 (WISP1) is increased in human scleroderma skin and idiopathic pulmonary fibrosis (IPF) lung. A recent study showed that WISP-1 mediates lung fibrosis in mice. In the current study, we investigated the function of WISP-1 in dermal fibrosis.

Methods: There is accumulating evidence for a role of Wnt-signaling pathway activation in connective tissue disorders, including dermal and lung fibrosis. In particular, expression of WNT1-inducible signaling protein–1 (WISP1) is increased in human scleroderma skin and idiopathic pulmonary fibrosis (IPF) lung. A recent study showed that WISP-1 mediates lung fibrosis in mice. In the current study, we investigated the function of WISP-1 in dermal fibrosis.

Results: Anti-WISP-1 mAb treatment reduced skin fibrosis in the GVHD model, as documented by reduction of hydroxyproline content and Masson’s trichrome staining in skin at week 4 post-graft. Gene expression analysis showed a concomitant reduction of GVHD-associated Th2 responses in skin, including cytokine/receptor (IL-13, IL-4Rα) and chemokines (CCL2, CCL17 and CCL22). This Th2 profile reduction was associated with a broad-based reduction of the pro-Th2 TSLP-OX40L axis (TSLP, TSLPR, IL-7R, OX40L), suggesting that the TSLP/OX40L pathway may in part mediate the effect of WISP-1 on the Th2 response in GVHD. This view was supported with data generated from a separate study showing that anti-TSLP mAb treatment in GVHD-induced fibrosis reduces levels of Th2 (IL-13, IL-4) but not Th1 (IFN-γ) cytokines in skin and blood. TSLP neutralization also fully reduced GVHD-induced WISP-1 expression, further substantiating a functional link between WISP-1 and the TSLP/OX40L axis in fibrosis.

Conclusion: Consistent with the role of Wnt signaling pathways in fibrosis, WISP-1 neutralization reduces GVHD-induced skin fibrosis in part by affecting TSLP-OX40L-based Th2 responses. Interestingly, scleroderma shows increased dermal TSLP level and OX40L polymorphisms, suggesting that targeting WISP-1 may offer a valuable therapeutic strategy for the treatment of scleroderma and other skin fibrosis disorders.


Disclosure:

R. Lemaire,
None;

T. Burwell,
None;

R. Griffin,
None;

J. Bakken,
None;

J. Madary,
None;

L. Murray,
None;

R. Herbst,
None;

J. Connor,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/wisp-1-neutralization-reduces-gvhd-induced-skin-fibrosis-by-altering-tslp-ox40l-axis-dependent-th2-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology